EuroBiotech: More Articles of Note

(NS Newsflash/CC BY 2.0)

> Shares in GenSight tumbled after a phase 3 trial of its gene therapy missed its primary endpoint. The vision of Leber hereditary optic neuropathy patients enrolled in the trial improved after receiving the therapy, but the trial also reported improvements in the vision of untreated eyes. Statement

> Oryzon moved ORY-2001 into a phase 2a Alzheimer’s trial. Release

> Motif Bio began the rolling FDA submission for antibiotic iclaprim. Statement 


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

> ThromboGenics advanced anti-PlGF drug THR-317 after getting a look at phase 1/2 data. The next trial will assess the diabetic macular edema drug in combination with an anti-VEGF therapy. Release

> AC Immune picked tau small molecules to move into human testing in Alzheimer’s disease. A phase 1 trial is due to start by the end of the year. Statement

> Shares in Santhera rose after it wrapped up a clinical trial of congenital muscular dystrophy drug omigapil. Novartis originally developed the asset. Release 

Suggested Articles

The trial hit its primary endpoint by the time of an interim analysis, enabling Chi-Med to stop the study and start work on a filing for approval.

The anticipated fundraising haul will bankroll development of a pipeline of RAS programs up to the completion of IND-enabling studies.

As GlaxoSmithKline looks to start a 23andMe-partnered test this year, the Big Pharma is increasingly looking to tech for its R&D.